Leigh-Ann Durant, Esq.
For the past decade, Attorney Durant has served at EMD Serono, Inc., the US affiliate of Merck KGaA, Darmstadt, Germany, where she is the Head lawyer for all R&D activities in the US from early development to launch. She has structured, negotiated and closed numerous high-profile, complex strategic collaborations and transactions, in/out-licensing transactions and business development agreements.
Earlier in her career, Attorney Durant was a Partner at Nixon Peabody LLP, a Global 100 Law Firm, in its Complex Commercial Litigation, Pharma and FDA Practice Groups. For over two decades, Attorney Durant has served on a variety of boards of directors, executive committees and has led various legal and non-profit organizations as President. She has received numerous awards, including the national Top 30 Emerging Leaders in the Pharmaceutical Industry Award and the Massachusetts In-House Leaders In The Law Award, Woman of the Year in Law Award and Top 10 Women Lawyers in Massachusetts Award.
Attorney Durant received a B.A. with a double major with honors in Foreign Affairs/International Relations and Political Science from Miami University, Oxford, OH, and a Juris Doctorate, cum laude, from Suffolk University Law School, Boston, MA. After law school, she served as the appellate law clerk for the late Chief Justice Joseph R. Weisberger of the Supreme Court of Rhode Island.
In five years at Astellas, Dr. Klohs helped build Oncology into a global business with several marketed products including Tarceva® and Xtandi® and helped build a robust oncology pipeline through in-licensing, the acquisition of OSI, and internal discovery. He was responsible for the successful filings of NDAs and MAAs for Xtandi (enzalutamide) and Tarceva (sNDA). Dr. Klohs’s previous experience includes acting head of Oncology Clinical Sciences at Takeda Global R&D and Executive Director of Oncology Drug Development at Pfizer, Inc. At Takeda, he led both early and late-stage Development Teams in Oncology, while at Pfizer, he was responsible for Development Teams from mid-Discovery through POC with additional experience in NDA filing of pentostatin/Nipent. Dr. Klohs led development teams at Pfizer and Parke-Davis to more than 14 successful IND filings and Phase 1 starts as well as leading late stage programs in biologics including monoclonal antibodies and an oncolytic adenovirus. Prior to his experience in drug development for oncology, he led discovery efforts at Warner-Lambert/Parke Davis Pharmaceutical Research in oncology for 16 years in a number of areas including antiangiogenic agents, multiple drug resistance, histone deacetylase inhibitors, and antifolates.